University of Texas- Southwestern (Pediatrics and Adults)
Welcome,         Profile    Billing    Logout  
 1 Trial 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Raskin, Philip
MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

Completed
4
141
US
Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1
03/24
06/24
DESIGNATE, NCT05574335: Siplizumab in T1DM

Active, not recruiting
1/2
120
US
Siplizumab, TCD 601
National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes Mellitus
12/26
12/27
2IQP, NCT05785832: A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes

Completed
N/A
319
Canada, US
t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
Tandem Diabetes Care, Inc., Jaeb Center for Health Research
Type 2 Diabetes Treated With Insulin
09/24
09/24
Jordan, Lin
MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

Completed
4
141
US
Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1
03/24
06/24
2IQP, NCT05785832: A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes

Completed
N/A
319
Canada, US
t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
Tandem Diabetes Care, Inc., Jaeb Center for Health Research
Type 2 Diabetes Treated With Insulin
09/24
09/24

Download Options